199 related articles for article (PubMed ID: 30353615)
21. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
del Rivero J; Kohn EC
Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
[TBL] [Abstract][Full Text] [Related]
22. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
Alruwaili MM; Zonneville J; Naranjo MN; Serio H; Melendy T; Straubinger RM; Gillard B; Foster BA; Rajan P; Attwood K; Chatley S; Iyer R; Fountzilas C; Bakin AV
Cell Rep Med; 2024 Mar; 5(3):101434. PubMed ID: 38387463
[TBL] [Abstract][Full Text] [Related]
23. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
24. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
25. Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells.
Raineri A; Prodomini S; Fasoli S; Gotte G; Menegazzi M
Biochem Pharmacol; 2019 Sep; 167():173-181. PubMed ID: 31185226
[TBL] [Abstract][Full Text] [Related]
26. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
27. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
28. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.
Francica P; Rottenberg S
Genome Med; 2018 Dec; 10(1):101. PubMed ID: 30593284
[TBL] [Abstract][Full Text] [Related]
30. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
[TBL] [Abstract][Full Text] [Related]
31. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
[TBL] [Abstract][Full Text] [Related]
32. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
Shah AP; Patel CN; Sureja DK; Sanghavi KP
Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
[TBL] [Abstract][Full Text] [Related]
33. Poly(ADP-ribose) polymerase inhibition: past, present and future.
Curtin NJ; Szabo C
Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
[TBL] [Abstract][Full Text] [Related]
34. PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells.
Bellio C; DiGloria C; Foster R; James K; Konstantinopoulos PA; Growdon WB; Rueda BR
Mol Cancer Res; 2019 Feb; 17(2):431-445. PubMed ID: 30401718
[TBL] [Abstract][Full Text] [Related]
35. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
36. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
37. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
38. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
39. Targeting cancer stem cells in the tumor microenvironment: An emerging role of PARP inhibitors.
Paul S; Sinha S; Kundu CN
Pharmacol Res; 2022 Oct; 184():106425. PubMed ID: 36075511
[TBL] [Abstract][Full Text] [Related]
40. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
Muvarak NE; Chowdhury K; Xia L; Robert C; Choi EY; Cai Y; Bellani M; Zou Y; Singh ZN; Duong VH; Rutherford T; Nagaria P; Bentzen SM; Seidman MM; Baer MR; Lapidus RG; Baylin SB; Rassool FV
Cancer Cell; 2016 Oct; 30(4):637-650. PubMed ID: 27728808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
